Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

Plenty of analysts on Wall Street think so. The company boasts an average price target of $93.39 (according to Yahoo! Finance ...

Sana Biotechnology's favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a ...

The shares are up 99% this year, as of Thursday close. In fact, they’ve climbed on every trading day so far in 2026. The ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

Investing.com -- IO Biotech Inc (NASDAQ:IOBT) stock plunged 46.5% Wednesday after the clinical-stage biopharmaceutical company announced it would explore strategic alternatives to maximize stockholder ...

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

Emkay Global Financial is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 637 in ...

Discover the PEG ratio's role in evaluating stock potential by balancing earnings growth with stock prices, aiding in ...